Is 5-ALA fluorescence of cerebral metastases a prognostic factor for local recurrence and overall survival?
5-Aminolevulinic acid
Cerebral metastases
In-brain-progression
Overall survival
Recurrence
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
07
06
2018
accepted:
28
11
2018
pubmed:
12
12
2018
medline:
31
5
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
5-Aminolevulinic acid (5-ALA) fluorescence-guided resection technique was first introduced for malignant glioma. However, the impact of the 5-ALA fluorescence behaviour of cerebral metastases is still unclear. Aim of this study was to determine the impact of PpIX-fluorescence on the local progression-free and overall survival. A secondary analysis was performed and included an updated follow-up of 136 patients comprised in two previous studies. Additionally, 82 new patients were included. All patients underwent surgical resection of cerebral metastasis and intraoperative estimation of 5-ALA-induced fluorescence. The 5-ALA fluorescence behaviour of cerebral metastases was correlated with the rate of local recurrences, the local progression-free and overall survival. 218 patients suffering from cerebral metastatic spread fulfilled the inclusion criteria and were analysed: complete surgical resection could be achieved in 123/218 patients (56.4%). Dichotomised degree of surgical resection (complete vs. incomplete or questionable complete resection) was not related to dichotomized 5-ALA fluorescence of cerebral metastases (p = 0.66). 51 patients (23.4%) developed a local in-brain progression within or at the border of the resection cavity. Of these, 8 patients showed a PpIX-fluorescent metastasis. There was a trend towards a correlation between a higher local in-brain progression in PpIX-non-fluorescent metastases (p = 0.03). Median time to local in-brain progression was 4 ± 11 months. PpIX-fluorescent and PpIX-non-fluorescent metastases showed a significantly different progression-free survival (p = 0.01). PpIX-positive and -negative metastases showed a significantly different overall survival (20 and 14 months respectively; p = 0.006). The 5-ALA fluorescence behaviour was related to the local progression-free and the overall survival in the present retrospective series and might be considered a prognostic marker. Further studies are required to appreciate the oncological impact of the 5-ALA induced fluorescence behaviour of cerebral metastases.
Sections du résumé
BACKGROUND
BACKGROUND
5-Aminolevulinic acid (5-ALA) fluorescence-guided resection technique was first introduced for malignant glioma. However, the impact of the 5-ALA fluorescence behaviour of cerebral metastases is still unclear. Aim of this study was to determine the impact of PpIX-fluorescence on the local progression-free and overall survival.
MATERIALS AND METHODS
METHODS
A secondary analysis was performed and included an updated follow-up of 136 patients comprised in two previous studies. Additionally, 82 new patients were included. All patients underwent surgical resection of cerebral metastasis and intraoperative estimation of 5-ALA-induced fluorescence. The 5-ALA fluorescence behaviour of cerebral metastases was correlated with the rate of local recurrences, the local progression-free and overall survival.
RESULTS
RESULTS
218 patients suffering from cerebral metastatic spread fulfilled the inclusion criteria and were analysed: complete surgical resection could be achieved in 123/218 patients (56.4%). Dichotomised degree of surgical resection (complete vs. incomplete or questionable complete resection) was not related to dichotomized 5-ALA fluorescence of cerebral metastases (p = 0.66). 51 patients (23.4%) developed a local in-brain progression within or at the border of the resection cavity. Of these, 8 patients showed a PpIX-fluorescent metastasis. There was a trend towards a correlation between a higher local in-brain progression in PpIX-non-fluorescent metastases (p = 0.03). Median time to local in-brain progression was 4 ± 11 months. PpIX-fluorescent and PpIX-non-fluorescent metastases showed a significantly different progression-free survival (p = 0.01). PpIX-positive and -negative metastases showed a significantly different overall survival (20 and 14 months respectively; p = 0.006).
CONCLUSION
CONCLUSIONS
The 5-ALA fluorescence behaviour was related to the local progression-free and the overall survival in the present retrospective series and might be considered a prognostic marker. Further studies are required to appreciate the oncological impact of the 5-ALA induced fluorescence behaviour of cerebral metastases.
Identifiants
pubmed: 30535595
doi: 10.1007/s11060-018-03066-y
pii: 10.1007/s11060-018-03066-y
doi:
Substances chimiques
Fluorescent Dyes
0
Aminolevulinic Acid
88755TAZ87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-553Références
Oncology (Williston Park). 2001 Sep;15(9):1144-54, 1157-8; discussion 1158, 1163-5
pubmed: 11589063
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
FASEB J. 2008 Feb;22(2):500-9
pubmed: 17875605
Brain Tumor Pathol. 2007;24(2):53-5
pubmed: 18095131
J Neurosurg. 2008 Feb;108(2):248-57
pubmed: 18240919
J Neurosurg. 2009 Apr;110(4):730-6
pubmed: 19072310
Curr Opin Neurol. 2009 Dec;22(6):645-9
pubmed: 19738467
J Neurosurg. 2010 Aug;113(2):181-9
pubmed: 20035574
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
J Neurosurg. 2011 Jul;115(1):11-7
pubmed: 21438658
Clin Oncol (R Coll Radiol). 2011 Nov;23(9):646-51
pubmed: 21592754
Acta Neurochir (Wien). 2011 Jul;153(7):1497-9
pubmed: 21604207
Acta Neurochir (Wien). 2012 Feb;154(2):223-8; discussion 228
pubmed: 22080159
Neurosurg Rev. 2012 Jul;35(3):381-91; discussion 391
pubmed: 22407140
Acta Neurochir (Wien). 2012 Nov;154(11):1981-6
pubmed: 22875595
Ecancermedicalscience. 2013 Apr 18;7:306
pubmed: 23653671
Acta Neurochir (Wien). 2014 Apr;156(4):653-60
pubmed: 24468884
Neurosurg Focus. 2014 Feb;36(2):E10
pubmed: 24484248
Neurosurg Focus. 2014 Feb;36(2):E3
pubmed: 24484256
J Neurooncol. 2014 Jun;118(2):363-367
pubmed: 24736830
Biomed Res Int. 2014;2014:207974
pubmed: 24971317
J Neurosurg. 2015 May;122(5):1132-43
pubmed: 25794344
Acta Neurochir (Wien). 2015 Jun;157(6):905-10; discussion 910-1
pubmed: 25845550
Clin Cancer Res. 2015 Sep 15;21(18):4194-200
pubmed: 25878329
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Acta Neurochir (Wien). 2015 Sep;157(9):1573-80
pubmed: 26156037
Neurosurg Rev. 2018 Jan;41(1):77-86
pubmed: 27392678
Oncotarget. 2016 Oct 11;7(41):66776-66789
pubmed: 27564260
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Neurosurg Rev. 2018 Jul;41(3):813-823
pubmed: 29260342
Neurosurg Rev. 2018 Oct;41(4):1079-1083
pubmed: 30039396
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
J Photochem Photobiol B. 1998 Sep;45(2-3):160-9
pubmed: 9868806